Small-Molecule Oncology Firm Debuts | Chemical & Engineering News
Volume 91 Issue 28 | p. 15 | Concentrates
Issue Date: July 15, 2013

Small-Molecule Oncology Firm Debuts

Department: Business
Keywords: biotechnology, oncology, small molecules, funding

Biotech company Array BioPharma and investment firm Aisling Capital have joined to form and fund Loxo Oncology to develop small-molecule drugs that treat cancer. Loxo’s first drug candidate is an Array-invented preclinical compound that targets an oncogenic activating mutation. The new firm will fund chemistry research at Array, which is eligible to receive up to $434 million in milestone payments. The partners say the collaboration between Loxo and Array is a solution to the biotech industry quandary of how to fund innovation without funding duplicative infrastructure.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment